MCID: ADL042
MIFTS: 35

Adult Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Adult Malignant Schwannoma

MalaCards integrated aliases for Adult Malignant Schwannoma:

Name: Adult Malignant Schwannoma 12 15
Adult Neurofibrosarcoma 71
Adult Mpnst 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8369
NCIt 49 C7814
UMLS 71 C0278622

Summaries for Adult Malignant Schwannoma

MalaCards based summary : Adult Malignant Schwannoma, also known as adult neurofibrosarcoma, is related to orbit rhabdomyosarcoma and orbit embryonal rhabdomyosarcoma. An important gene associated with Adult Malignant Schwannoma is NF1 (Neurofibromin 1), and among its related pathways/superpathways are ERK Signaling and Regulation of TP53 Activity. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Adult Malignant Schwannoma

Diseases related to Adult Malignant Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Related Disease Score Top Affiliating Genes
1 orbit rhabdomyosarcoma 10.6 NF1 MYOG
2 orbit embryonal rhabdomyosarcoma 10.5 NF1 MYOG
3 prostate embryonal rhabdomyosarcoma 10.5 NF1 MYOG
4 malignant glandular tumor of peripheral nerve sheath 10.5 NF1 B3GAT1
5 cellular neurofibroma 10.5 NF1 B3GAT1
6 mucoepidermoid esophageal carcinoma 10.5 TP53 SPP1
7 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
8 esophagus verrucous carcinoma 10.4 TP53 CDKN2A
9 childhood malignant schwannoma 10.4 SPP1 NF1 BIRC5
10 trachea carcinoma in situ 10.4 HRAS CDKN2A
11 vulvar melanoma 10.4 NF1 HRAS
12 ectomesenchymoma 10.4 MYOG HRAS
13 suppressor of tumorigenicity 3 10.4 TP53 CDKN2A
14 breast squamous cell carcinoma 10.3 TP53 HRAS
15 central nervous system hemangioma 10.3 NF1 CD34
16 mechanical ectropion 10.3 NF1 CD34
17 malignant triton tumor 10.3 NF1 MYOG B3GAT1
18 adult teratoma 10.3 TP53 HRAS
19 pacinian tumor 10.3 NF1 CD34
20 amyloid tumor 10.3 NF2 NF1
21 squamous cell papilloma 10.3 TP53 HRAS
22 neurilemmoma of the fifth cranial nerve 10.3 NF2 NF1
23 trigeminal nerve neoplasm 10.3 NF2 NF1
24 wolffian duct adenocarcinoma 10.3 TP53 HRAS
25 peripheral nerve schwannoma 10.3 NF2 NF1
26 chronic cervicitis 10.3 TP53 CDKN2A
27 vulvar intraepithelial neoplasia 10.3 TP53 CDKN2A BIRC5
28 familial retinoblastoma 10.3 TP53 NF1 CDKN2A
29 gastric liposarcoma 10.3 PIN1 CD34
30 liposarcoma of bone 10.3 MYOG CD34
31 spinal cord oligodendroglioma 10.3 TP53 NF1
32 fibrillary astrocytoma 10.3 TP53 NF1 CDKN2A
33 biliary tract benign neoplasm 10.3 TP53 HRAS
34 dedifferentiated liposarcoma 10.3 TP53 MYOG CDKN2A
35 sarcomatoid squamous cell skin carcinoma 10.3 MYOG CD34
36 hobnail hemangioma 10.3 MYOG CD34
37 vagina leiomyoma 10.3 CDKN2A CD34
38 oral leukoplakia 10.3 TP53 CDKN2A
39 rhabdoid cancer 10.3 TP53 MYOG CDKN2A
40 cervical polyp 10.3 MYOG CD34
41 heart sarcoma 10.3 MYOG CD34
42 heart leiomyosarcoma 10.3 CDKN2A CD34
43 liver sarcoma 10.3 MYOG CD34
44 mesenchymoma 10.3 MYOG CD34
45 extraosseous osteosarcoma 10.3 MYOG CD34
46 inflammatory liposarcoma 10.2 CDKN2A CD34
47 glomangiosarcoma 10.2 TP53 CD34
48 tumor of exocrine pancreas 10.2 TP53 HRAS
49 parameningeal embryonal rhabdomyosarcoma 10.2 TP53 MYOG
50 polyp of corpus uteri 10.2 NF2 NF1

Graphical network of the top 20 diseases related to Adult Malignant Schwannoma:



Diseases related to Adult Malignant Schwannoma

Symptoms & Phenotypes for Adult Malignant Schwannoma

GenomeRNAi Phenotypes related to Adult Malignant Schwannoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.06 HRAS
2 Decreased viability GR00221-A-1 10.06 CDKN2A HRAS
3 Decreased viability GR00221-A-2 10.06 HRAS MAX
4 Decreased viability GR00221-A-3 10.06 CDKN2A HRAS MAX NF2 PIN1
5 Decreased viability GR00221-A-4 10.06 CDKN2A
6 Decreased viability GR00402-S-2 10.06 CDKN2A HRAS MAX NF2 PIN1
7 Decreased cell migration GR00055-A-1 9.65 ACTG1 AURKA HRAS NF1 NF2
8 Increased Nanog expression GR00371-A-1 9.4 AURKA BIRC5 MAX
9 Increased Nanog expression GR00371-A-2 9.4 AURKA MAX
10 Increased Nanog expression GR00371-A-3 9.4 AURKA BIRC5 HRAS MAX
11 Increased Nanog expression GR00371-A-4 9.4 MAX
12 Increased Nanog expression GR00371-A-5 9.4 AURKA BIRC5
13 Increased cell migration GR00055-A-3 9.35 ACTG1 AURKA HRAS NF1 NF2

MGI Mouse Phenotypes related to Adult Malignant Schwannoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 AURKA BIRC5 CD34 CDKN2A FOXM1 MAX
2 growth/size/body region MP:0005378 10.35 ACTG1 AURKA CDKN2A CXCL14 HRAS MAX
3 homeostasis/metabolism MP:0005376 10.34 BIRC5 CD34 CDKN2A CXCL14 FOXM1 HRAS
4 mortality/aging MP:0010768 10.33 ACTG1 AURKA B3GAT1 BIRC5 CDKN2A CXCL14
5 behavior/neurological MP:0005386 10.32 ACTG1 B3GAT1 CDKN2A CXCL14 HRAS MYOG
6 embryo MP:0005380 10.26 ACTG1 AURKA BIRC5 CDKN2A MAX MYOG
7 integument MP:0010771 10.24 ACTG1 CD34 CDKN2A HRAS MYOG NF1
8 immune system MP:0005387 10.21 BIRC5 CD34 CDKN2A CXCL14 FOXM1 NF1
9 endocrine/exocrine gland MP:0005379 10.2 BIRC5 CDKN2A FOXM1 HRAS NF1 NF2
10 digestive/alimentary MP:0005381 10.11 ACTG1 CDKN2A FOXM1 HRAS NF1 SOX9
11 nervous system MP:0003631 10.07 ACTG1 B3GAT1 CDKN2A HRAS NF1 NF2
12 neoplasm MP:0002006 10.06 AURKA CD34 CDKN2A FOXM1 HRAS NF1
13 muscle MP:0005369 10.03 ACTG1 CDKN2A FOXM1 MYOG NF1 SOX9
14 liver/biliary system MP:0005370 10.02 CDKN2A CXCL14 FOXM1 NF1 NF2 SPP1
15 no phenotypic analysis MP:0003012 9.87 AURKA CDKN2A CXCL14 HRAS MYOG SOX9
16 reproductive system MP:0005389 9.81 B3GAT1 CDKN2A CXCL14 NF1 NF2 PIN1
17 renal/urinary system MP:0005367 9.8 CXCL14 HRAS NF1 NF2 SOX9 SPP1
18 respiratory system MP:0005388 9.61 CDKN2A FOXM1 HRAS MYOG NF1 NF2
19 vision/eye MP:0005391 9.23 AURKA CDKN2A NF1 NF2 PIN1 SOX9

Drugs & Therapeutics for Adult Malignant Schwannoma

Drugs for Adult Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
6
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
7
Isophosphamide mustard Phase 3 0
8 Etoposide phosphate Phase 3
9 Topoisomerase Inhibitors Phase 2, Phase 3
10 Alkylating Agents Phase 2, Phase 3
11 Anti-Bacterial Agents Phase 2, Phase 3
12 Antibiotics, Antitubercular Phase 2, Phase 3
13
Liposomal doxorubicin Phase 2, Phase 3 31703
14
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
15
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
16 Exatecan Investigational Phase 2 171335-80-1
17
Camptothecin Experimental Phase 2 7689-03-4
18 topoisomerase I inhibitors Phase 2
19 Protein Kinase Inhibitors Phase 2
20
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
21 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
22 Angiogenesis Inhibitors Phase 2
23 Immunosuppressive Agents Phase 2
24 Immunologic Factors Phase 2
25 Adjuvants, Immunologic Phase 2
26
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
27 Anti-Inflammatory Agents Phase 1
28 Anti-Inflammatory Agents, Non-Steroidal Phase 1
29 Analgesics, Non-Narcotic Phase 1
30 Cyclooxygenase 2 Inhibitors Phase 1
31 Cyclooxygenase Inhibitors Phase 1
32 Antirheumatic Agents Phase 1
33 Analgesics Phase 1

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
2 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
3 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
4 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
9 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
10 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
11 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
12 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
13 U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II Completed NCT00068367 Phase 2 erlotinib hydrochloride
14 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
15 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
16 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
17 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
18 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
19 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
20 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas Terminated NCT00740597 Phase 2
21 Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
22 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
23 VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK] Unknown status NCT00900211

Search NIH Clinical Center for Adult Malignant Schwannoma

Genetic Tests for Adult Malignant Schwannoma

Anatomical Context for Adult Malignant Schwannoma

MalaCards organs/tissues related to Adult Malignant Schwannoma:

40
Lung, Bone, Breast, Skin, Prostate, Spinal Cord, Heart

Publications for Adult Malignant Schwannoma

Articles related to Adult Malignant Schwannoma:

# Title Authors PMID Year
1
Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. 61
24390465 2014

Variations for Adult Malignant Schwannoma

Expression for Adult Malignant Schwannoma

Search GEO for disease gene expression data for Adult Malignant Schwannoma.

Pathways for Adult Malignant Schwannoma

Pathways related to Adult Malignant Schwannoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 TP53 SPP1 SOX9 NF1 MAX HRAS
2
Show member pathways
12.75 TP53 PIN1 CDKN2A BIRC5 AURKA
3 12.63 TP53 MAX HRAS CDKN2A BIRC5
4
Show member pathways
12.56 TP53 HRAS CDKN2A BIRC5 ACTG1
5 12.13 TP53 PIN1 FOXM1 CDKN2A AURKA
6 11.91 TP53 HRAS FOXM1 CDKN2A
7 11.86 TP53 NF1 MAX AURKA
8 11.61 TP53 MAX BIRC5
9 11.53 TP53 CDKN2A BIRC5
10 11.52 TP53 HRAS CDKN2A
11 11.48 TP53 HRAS CXCL14 CDKN2A
12 11.43 TP53 MAX HRAS
13 11.07 TP53 NF2 NF1 HRAS CDKN2A
14 10.99 TP53 BIRC5 AURKA

GO Terms for Adult Malignant Schwannoma

Cellular components related to Adult Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 TP53 SOX9 PIN1 MYOG MAX HRAS
2 nucleus GO:0005634 9.77 TP53 SOX9 PIN1 NF2 NF1 MYOG
3 chromosome passenger complex GO:0032133 8.62 BIRC5 AURKA

Biological processes related to Adult Malignant Schwannoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 TP53 SOX9 PIN1 MYOG MAX HRAS
2 negative regulation of transcription, DNA-templated GO:0045892 9.96 TP53 SOX9 FOXM1 CDKN2A BIRC5
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 SPP1 SOX9 MYOG FOXM1 CDKN2A
4 positive regulation of gene expression GO:0010628 9.89 TP53 SOX9 HRAS CDKN2A CD34
5 regulation of apoptotic process GO:0042981 9.85 TP53 SOX9 NF2 BIRC5
6 regulation of cell proliferation GO:0042127 9.78 TP53 SOX9 NF2 NF1
7 negative regulation of protein kinase activity GO:0006469 9.71 NF2 NF1 CDKN2A
8 cell cycle GO:0007049 9.7 TP53 PIN1 MYOG FOXM1 CDKN2A BIRC5
9 positive regulation of neuron apoptotic process GO:0043525 9.63 TP53 PIN1 NF1
10 regulation of protein stability GO:0031647 9.62 PIN1 NF2 CDKN2A AURKA
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 TP53 FOXM1
12 negative regulation of cell-matrix adhesion GO:0001953 9.58 NF2 NF1 CDKN2A
13 replicative senescence GO:0090399 9.57 TP53 CDKN2A
14 Ras protein signal transduction GO:0007265 9.56 TP53 NF1 HRAS CDKN2A
15 regulation of protein localization to nucleus GO:1900180 9.52 PIN1 NF2
16 negative regulation of neuroblast proliferation GO:0007406 9.51 TP53 NF1
17 negative regulation of gene expression GO:0010629 9.43 TP53 SOX9 MAX HRAS CD34 AURKA
18 negative regulation of cell proliferation GO:0008285 9.17 TP53 SOX9 NF2 NF1 MYOG HRAS

Sources for Adult Malignant Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....